US · Healthcare · Drug Manufacturers - General
EPS came in at 0.96 against a street estimate of 0.82 — a beat of 17.1%.
Analysts rate Novo Nordisk A/S a hold (3 buy, 10 hold, 1 sell out of 14) with an average price target of $45.81.
| Fund | Stake |
|---|---|
| Dodge & Cox | 0.46% |
| Loomis, Sayles & Company LP | 0.42% |
| Franklin Templeton Inc | 0.30% |
| T. Rowe Price Associates, Inc. | 0.27% |
| Morgan Stanley - Brokerage Accounts | 0.26% |
| Bank of America Corp | 0.25% |
| Capital Research & Mgmt Co - Division 3 | 0.22% |
| Folketrygdfondet | 0.22% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2023 HEADLINE NUMBERS • Novo Nordisk repurchased 1,245,000 B shares between 5 October and 9 October 2026 for a total of DKK 311,605,554. • The shares wer | 2026-10-13 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Novo Nordisk repurchased 1,225,000 B shares between 28 September and 2 October 2026. • The shares were bought for a total of DKK | 2026-10-06 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Novo Nordisk said the US FDA review of denecimig for haemophilia A remains ongoing, with no new timeline for regulatory action. • | 2026-10-05 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Novo Nordisk repurchased 1,205,000 B shares between 21 September and 25 September 2026 for a total of DKK 309,919,096. • The shar | 2026-09-28 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Novo Nordisk repurchased 1,090,000 B shares from 14–18 September 2026 for DKK 303,736,458, at an average price of DKK 278.84 per s | 2026-09-21 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Novo Nordisk announced on September 17, 2026, that the European Medicines Agency’s Committee for Medicinal Products for Human Use | 2026-09-17 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Novo Nordisk repurchased 1,050,000 B shares from 7–11 September 2026 for DKK 304,412,195, at average prices ranging from DKK 278.6 | 2026-09-15 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 reported sales were DKK 78,488 million, up 3% at constant exchange rates (CER). • Q2 adjusted sales were DKK 78,488 milli | 2026-08-04 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.58 / share ex-date Aug 17, 2026 · pay Aug 25, 2026 | 2026-08-17 |
| Dividend | $1.27 / share ex-date Mar 30, 2026 · pay Apr 8, 2026 | 2026-03-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Novo Nordisk A/S — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.